Lila Hope focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships and platform discovery and option deals. In addition, she counsels clients' management, operational and legal teams on day-to-day matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions.  Lila maintains an active practice in cross-border licensing transactions, concluding over 20 transactions involving Asian biotechnology companies between 2015 and 2021.

Download full bio 


  • Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines 

  • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 

  • CardioKinetix Completes $50 Million Financing 

  • Adamas Pharmaceuticals Initial Public Offering 

  • Ascendis Pharma closes $124 million IPO 

  • View all


  • Duke University School of Law
    JD, magna cum laude, 2002

  • Stanford University
    PHD, Cancer Biology

  • Oregon Graduate Institute
    MS, 1993

Admissions & Credentials



  • American Bar Association

Rankings & Accolades

    Chambers USA: Life Sciences: Corporate/Commercial – California (2020-2022)

    Legal 500: Healthcare: Life Sciences

"Lila has tremendous experience in licensing and complex agreements. She has a pragmatic approach and really understands the business needs of her clients."

Chambers USA: Life Sciences: Corporate/Commercial – California (2022)